TAMOXIFEN Sandoz 10 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

tamoxifen sandoz 10 mg

sandoz pharmaceuticals d.d., slovinsko - tamoxifén - 44 - cytostatica

TAMOXIFEN Sandoz 20 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

tamoxifen sandoz 20 mg

sandoz pharmaceuticals d.d., slovinsko - tamoxifén - 44 - cytostatica

Zitazonium 20 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zitazonium 20 mg

egis pharmaceuticals plc, maďarsko - tamoxifén - 44 - cytostatica

Zitazonium 10 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zitazonium 10 mg

egis pharmaceuticals plc, maďarsko - tamoxifén - 44 - cytostatica

Verzenios Európska únia - slovenčina - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - neoplazmy prsníkov - antineoplastické činidlá - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.